REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Tevogen Bio Holdings (NASDAQ:TVGN) reported significant growth in institutional ownership, with a 60% increase in holdings as of March 31, 2025, compared to December 31, 2024. Leading institutional investors Vanguard and BlackRock increased their combined holdings by 151%.
Among the 51 institutional investors holding Tevogen stock, 73% either increased or maintained their positions. Notably, only one current institutional holder maintained their position from the previous year, indicating substantial new investor interest. The company's growth is supported by Tevogen.AI advancements, new patent activity, collaboration with Microsoft and Databricks, and plans to establish a GMP cell manufacturing facility.
Tevogen Bio Holdings (NASDAQ:TVGN) ha registrato una crescita significativa della partecipazione istituzionale, con un aumento del 60% delle quote al 31 marzo 2025 rispetto al 31 dicembre 2024. I principali investitori istituzionali, Vanguard e BlackRock hanno incrementato le loro partecipazioni combinate del 151%.
Tra i 51 investitori istituzionali che detengono azioni Tevogen, il 73% ha aumentato o mantenuto le posizioni. È significativo che soltanto un attuale detentore istituzionale abbia mantenuto la sua posizione rispetto all'anno precedente, a indicare un notevole interesse di nuovi investitori. La crescita della società è sostenuta dai progressi di Tevogen.AI, da nuova attività brevettuale, dalla collaborazione con Microsoft e Databricks e dai piani per avviare un impianto GMP per la produzione cellulare.
Tevogen Bio Holdings (NASDAQ:TVGN) registró un crecimiento significativo en la propiedad institucional, con un aumento del 60% en las participaciones al 31 de marzo de 2025 respecto al 31 de diciembre de 2024. Los principales inversores institucionales, Vanguard y BlackRock incrementaron sus participaciones combinadas en un 151%.
De los 51 inversores institucionales que poseen acciones de Tevogen, el 73% aumentó o mantuvo sus posiciones. Cabe destacar que solo un titular institucional actual mantuvo su posición respecto al año anterior, lo que indica un significativo interés de nuevos inversores. El crecimiento de la compañía está respaldado por los avances de Tevogen.AI, nueva actividad de patentes, la colaboración con Microsoft y Databricks y los planes para establecer una planta de fabricación celular con certificación GMP.
Tevogen Bio Holdings (NASDAQ:TVGN)는 기관 보유 비중에서 큰 성장을 보였으며, 2025년 3월 31일 기준 보유량이 2024년 12월 31일 대비 60% 증가했습니다. 주요 기관 투자자인 Vanguard와 BlackRock은 합산 보유분을 151% 늘렸습니다.
Tevogen 주식을 보유한 51개 기관 투자자 중 73%가 보유를 늘렸거나 유지했습니다. 특히 현재의 기관 보유자 중 전년 대비 포지션을 유지한 경우는 단 한 곳뿐으로, 이는 새로운 투자자들의 유입이 상당했음을 시사합니다. 회사의 성장은 Tevogen.AI의 발전, 신규 특허 활동, Microsoft 및 Databricks와의 협업, 그리고 GMP 수준의 세포 제조 시설 설립 계획에 의해 뒷받침되고 있습니다.
Tevogen Bio Holdings (NASDAQ:TVGN) a enregistré une forte progression de la détention institutionnelle, avec une hausse de 60% des positions au 31 mars 2025 par rapport au 31 décembre 2024. Les principaux investisseurs institutionnels, Vanguard et BlackRock, ont augmenté leurs participations combinées de 151%.
Parmi les 51 investisseurs institutionnels détenant des actions Tevogen, 73% ont augmenté ou maintenu leurs positions. Il est notable qu'un seul détenteur institutionnel actuel ait maintenu sa position par rapport à l'année précédente, ce qui témoigne d'un intérêt considérable de la part de nouveaux investisseurs. La croissance de l'entreprise est soutenue par les progrès de Tevogen.AI, une nouvelle activité de brevets, la collaboration avec Microsoft et Databricks, ainsi que des projets de création d'une usine de fabrication cellulaire conforme aux normes GMP.
Tevogen Bio Holdings (NASDAQ:TVGN) verzeichnete ein deutliches Wachstum der institutionellen Anteilseignerschaft: Die Bestände stiegen zum 31. März 2025 im Vergleich zum 31. Dezember 2024 um 60%. Führende institutionelle Anleger, Vanguard und BlackRock erhöhten ihre kombinierten Bestände um 151%.
Von den 51 institutionellen Investoren, die Tevogen-Aktien halten, haben 73% ihre Positionen erhöht oder beibehalten. Bemerkenswert ist, dass nur ein aktueller institutioneller Inhaber seine Position gegenüber dem Vorjahr beibehalten hat, was auf erhebliches Interesse neuer Investoren hindeutet. Das Wachstum des Unternehmens wird durch Fortschritte bei Tevogen.AI, neue Patentaktivitäten, die Zusammenarbeit mit Microsoft und Databricks sowie Pläne zum Aufbau einer GMP-zertifizierten Zellproduktionsanlage gestützt.
- Institutional ownership increased by 60% quarter-over-quarter
- Vanguard and BlackRock increased combined holdings by 151%
- 73% of institutional holders increased or maintained positions
- Strategic partnerships with Microsoft and Databricks
- Plans for establishing own GMP cell manufacturing facility
- Company needs to raise additional capital to execute business plan
- Limited operating history poses risks
- Only one institutional holder remained from previous year, indicating high turnover
Insights
Tevogen's 60% institutional ownership growth and 151% increase from BlackRock/Vanguard signals significant investor confidence in its biotech developments.
The 60% increase in institutional ownership of Tevogen's stock represents a substantial vote of confidence from sophisticated market participants. When major institutional investors like Vanguard and BlackRock increase their holdings by 151%, it typically signals positive assessments of the company's fundamentals and growth trajectory. The fact that 73% of institutional holders either maintained or increased their positions further reinforces this positive sentiment.
Particularly noteworthy is that only one current institutional holder was present a year ago, indicating a dramatic influx of new institutional investors. This pattern often emerges when a company transitions from speculative to more established status in investors' evaluations. The breadth of institutional interest – now spanning 51 investment managers – provides a more stable shareholder base and potentially reduces volatility.
These institutional movements appear linked to Tevogen's strategic developments in AI technology advancements, new patent activity, and partnerships with tech leaders Microsoft and Databricks. The planned establishment of an in-house GMP cell manufacturing facility represents vertical integration that could improve margins and operational control. This ownership shift suggests the market is recognizing Tevogen's evolution in developing targeted therapies for cancers and infectious diseases, though concrete clinical progress metrics weren't specified in this release.
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
As reported on March 31, 2025, institutional ownership of Tevogen common stock increased by
“Increased institutional ownership is widely regarded as a sign of confidence in a company’s fundamentals and long-term growth potential,” said Tapan Shah, Tevogen’s Head of Investor Relations. “We’re encouraged not only by the rise in percentage ownership but also by the growth in the number of institutional holders. Tevogen.AI advancements, such as new patent activity and a collaboration with Microsoft and Databricks, combined with Tevogen’s planned establishment of its own GMP cell manufacturing facility, highlight the Company’s trajectory toward developing targeted therapies for cancers and infectious diseases.”
The Company will provide another institutional ownership update following the next SEC reporting period.
Forward-Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
FAQ
What was the increase in Tevogen's (TVGN) institutional ownership in Q1 2025?
How many institutional investors increased their positions in Tevogen (TVGN)?
What are Tevogen's (TVGN) major business developments in 2025?
What are the main risks facing Tevogen (TVGN)?
How has institutional investor retention changed for Tevogen (TVGN) since 2024?
